Balanced news tone
News Sentiment
U2TH34 sentiment intelligence
United Therapeutics Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
85/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value.
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 10 Jul 2026 22:29
- Source
- GuruFocus
United Therapeutics director Jan Malcolm sells $178,941 in stock By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:44
- Source
- Investing.com South Africa
United Therapeutics Corp (UTHR) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 88/100
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 22:33
- Source
- GuruFocus
United Therapeutics CEO Rothblatt sells $5.2m in company stock By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 18:54
- Source
- Investing.com South Africa
United Therapeutics Earnings Preview: Tyvaso Growth Takes Center Stage
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- EBC Financial Group
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035 - United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 02 Apr 2026 07:00
- Source
- Market source
United Therapeutics shares surge after positive IPF trial results
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Proactive financial news
United Therapeutics Surges Amid Successful Phase 3 Trials
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Mar 2026 07:00
- Source
- timothysykes.com
United Therapeutics (UTHR) Plans New Inhaler, Impacting MannKind (MNKD) and Liquidia (LQDA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Feb 2026 08:00
- Source
- GuruFocus
Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Nov 2025 08:00
- Source
- Market source
Tvardi Therapeutics’ stock crashes on Phase II IPF flop
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Oct 2025 07:00
- Source
- Clinical Trials Arena
Insider Sell: United Therapeutics Corp (UTHR) Chairperson & CEO Martine Rothblatt Sells 30,000 Shares
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 19 Mar 2024 07:00
- Source
- GuruFocus
EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Sep 2023 07:00
- Source
- GuruFocus
United Therapeutics Stock Price Forecast. Should You Buy UTHR?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 02 Dec 2020 23:54
- Source
- StockInvest.us